What is the current stock price of Fagron N.V. (ARSUF)?

As of the latest market data, Fagron N.V. (ARSUF) is trading at $26.53. The stock has seen a loss of -1.74% today.

Does Fagron N.V. (ARSUF) pay a dividend?

Based on current data, Fagron N.V. does not have a confirmed active dividend policy.

What is the market cap of Fagron N.V.?

The current market capitalization of Fagron N.V. (ARSUF) is approximately unavailable.

ARSUF

Fagron N.V.·Healthcare

26.53

1.741%(−0.47)

Market Closed

28.40

7.049%(+1.87)

After Hours

Last Updated: — ET

52W L: $20.0352W H: $27.00

ARSUF NEWS

seekingalpha.com

1d ago

Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript

globenewswire.com

1d ago

Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meeting.

globenewswire.com

2d ago

Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER 1 ), supported by incremental M&A contribution and outstanding performance in Latin America Organic growth at CER of 3.2%, reflecting positive contributions from all regions Positive momentum in the roll out of our Brands strategy while operational excellence initiatives continue to deliver benefits Completed the Pharmavit acquisition in the Netherlands, with integration of all recently closed transactions progressing as planned FY 2026 guidance: mid- to high-single digit organic sales growth at CER and a REBITDA margin of c.

globenewswire.com

Mar 31

Fagron increases share capital through exercise subscription rights

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84.

seekingalpha.com

Feb 16

Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript

Company Profile

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

3,828

IPO Date

2017-02-21

Beta

0.33

Websitewww.fagron.com↗